Description

DuPont Has A $10 Million Water Delay Investors Cannot Ignore!

DuPont reported first quarter 2026 financial results that exceeded prior guidance, marked by 4% net sales growth year-over-year on a 2% organic growth basis and favorable currency impacts. The company reported a 15% increase in operating EBITDA to $414 million and an operating EBITDA margin expansion of 230 basis points to 24.6%, driven by both favorable product mix and strong productivity gains. Adjusted earnings per share on a reported basis rose 53% to $0.55, while on a pro-forma basis, reflecting adjustments for corporate costs, interest, and taxes, EPS increased 20%. Segment performance was mixed, with Healthcare & Water Technologies achieving 6% net sales growth aided by strength in medical packaging and biopharma. However, the Water business faced low- to mid-single-digit organic sales declines impacted by logistical disruptions due to the Middle East conflict, estimated to have delayed approximately $10 million of sales in the quarter.